ClinicalTrials.gg
CompletedNCT01464424Updated Sep 13, 2013Results posted

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

A Phase 4 interventional study of Travoprost 0.004% ophthalmic solution and Bimatoprost 0.01% ophthalmic solution in Glaucoma, Ocular Hypertension and Open-Angle Glaucoma, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-13.

Primary conditionGlaucoma, Open-AngleRegistry: GlaucomaReclassifiedWhy we changed it
Registry
Glaucoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Glaucoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
29th of 45
84 · median 135
Started
2011
with 8 others
Phase 4
22 of 46
2 open now
Registered
32nd of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 29th largest by enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2011, is one of 22 in phase 4, and was the 32nd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study was to assess efficacy and tolerability of travoprost 0.004% vs. bimatoprost 0.01% during the after office hour period (4 pm to 8 pm) in subjects with open-angle glaucoma or ocular hypertension after 6 weeks of treatment.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension
  • Open-Angle Glaucoma

Browse trials for

Keywords

  • Glaucoma
  • Ocular Hypertension
  • Open-Angle Glaucoma
  • Intraocular Pressure
04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

This study's enrollment of 84 is close to the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.

Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glaucoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT) in at least one eye.
  • Non-study eye: Intraocular pressure (IOP) able to be controlled with no pharmacologic therapy or on the study medicine alone.
  • Willing to discontinue the use of all other ocular hypotensive medications prior to receiving study medication and for the entire course of the study.
  • Able to follow instructions, self instill study article, and attend all study visits.
  • Best-corrected Snellen visual acuity of 20/200 or better in each eye.
  • Sign Ethics Committee reviewed and approved form.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Known medical history of allergy, or poor tolerance to any component of the preparations used in this study.
  • Any abnormality preventing applanation tonometry in either eye.
  • Dry eye previously or currently being treated with punctal plugs, punctal cautery, Restasis®, or topical ocular .
  • Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye.
  • Intraocular conventional or laser surgery >3 months prior to consent.
  • Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.
  • Progressive retinal or optic nerve disease from any cause.
  • Use of any systemic medications known to affect IOP which have not been on a stable course for at least 7 days prior to Screening or an anticipated change in dosage during the course of the study.
  • Any , serious, or severe medical condition.
  • Women of who are pregnant, lactating, or not using reliable means of .
  • Participation in any other study within 30 days prior to Screening.
  • Use of any systemic (oral), injectable or topical steroids.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Other
    TRAVATAN, then LUMIGAN

    Travoprost 0.004% ophthalmic solution (TRAVATAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by bimatoprost 0.01% ophthalmic solution (LUMIGAN), same dose, same duration, as randomized, for a total duration of 12 weeks

    Drug: Travoprost 0.004% ophthalmic solution · Drug: Bimatoprost 0.01% ophthalmic solution

  • Other
    LUMIGAN, then TRAVATAN

    Bimatoprost 0.01% ophthalmic solution (LUMIGAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by travoprost 0.004% ophthalmic solution (TRAVATAN), same dose, same duration, as randomized, for a total duration of 12 weeks

    Drug: Travoprost 0.004% ophthalmic solution · Drug: Bimatoprost 0.01% ophthalmic solution

Interventions

07

What researchers measure

Primary outcomes

  1. Overall Mean Intraocular Pressure (IOP)

    IOP was measured at three after office hour evaluation time points (4 pm, 6 pm, and 8 pm) for an overall mean. The three timepoints correspond to 20, 22, and 24 hours post dose. Efficacy analysis was performed for one eye only, i.e., the designated study eye. Per-protocol dataset was pre-specified for this non-inferiority analysis.

    Time frame: Week 6

Secondary outcomes

  1. Mean IOP at Each After Office Hour Evaluation Timepoint

    IOP was measured at three after office hour evaluation time points (4 pm, 6 pm, and 8 pm). The three timepoints correspond to 20, 22, and 24 hours post dose. Efficacy analysis was performed for one eye only, i.e., the designated study eye.

    Time frame: Week 6: 4 pm, 6 pm, 8 pm

08

Results

Posted Sep 4, 2013

Participant flow

Subjects were recruited from 2 study centers located in the US.

Period 1, First 6 Weeks
Participant flow — Period 1, First 6 Weeks
MilestoneTRAVATAN, Then LUMIGANLUMIGAN, Then TRAVATAN
Started4242
Completed4241
Not completed01
Withdrew: Adverse event01
Period 2, Second 6 Weeks
Participant flow — Period 2, Second 6 Weeks
MilestoneTRAVATAN, Then LUMIGANLUMIGAN, Then TRAVATAN
Started4241
Completed4241
Not completed00

Outcome measures

SecondaryMean IOP at Each After Office Hour Evaluation Timepoint

IOP was measured at three after office hour evaluation time points (4 pm, 6 pm, and 8 pm). The three timepoints correspond to 20, 22, and 24 hours post dose. Efficacy analysis was performed for one eye only, i.e., the designated study eye.

Time frame:
Week 6: 4 pm, 6 pm, 8 pm
Reported as:
Mean · millimeters mercury (mmHg)
Mean IOP at Each After Office Hour Evaluation Timepoint
millimeters mercury (mmHg)TRAVATANLUMIGAN
4 pm (20 hours post dose)17.74 ± 3.09917.08 ± 2.808
6 pm (22 hours post dose)17.52 ± 2.83617.32 ± 3.055
8 pm (24 hours post dose)17.06 ± 2.84017.26 ± 2.890
PrimaryOverall Mean Intraocular Pressure (IOP)

IOP was measured at three after office hour evaluation time points (4 pm, 6 pm, and 8 pm) for an overall mean. The three timepoints correspond to 20, 22, and 24 hours post dose. Efficacy analysis was performed for one eye only, i.e., the designated study eye. Per-protocol dataset was pre-specified for this non-inferiority analysis.

Time frame:
Week 6
Reported as:
Mean · millimeters mercury (mmHg)
Overall Mean Intraocular Pressure (IOP)
millimeters mercury (mmHg)TRAVATANLUMIGAN
Overall Mean Intraocular Pressure (IOP)17.45 ± 2.66417.22 ± 2.605

Adverse events

Collected over Adverse events were collected for the duration of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TRAVATAN—0/84 (0%)0/84 (0%)
LUMIGAN—0/84 (0%)0/84 (0%)

Baseline characteristics

This reporting group includes all enrolled subjects.

Age Continuous
Age Continuous(years)Overall
Mean58.7 ± 11.41
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female55
Male29
Region of Enrollment
Region of Enrollment(participants)Overall
United States84
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • DuBiner HB, Hubatsch DA. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial. BMC Ophthalmol. 2014 Nov 28;14:151. doi: 10.1186/1471-2415-14-151. PubMed 25432143 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2011
First posted
Nov 3, 2011
Start
Oct 2011
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Sep 4, 2013
Last update
Sep 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01464424
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Nov 3, 2011
Start date
Oct 2011
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Sep 4, 2013
Last update
Sep 13, 2013

Study contacts

Doug Hubatsch, MS
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Travoprost · Bimatoprost

Start the discussion